[go: up one dir, main page]

WO2011041609A3 - Formulations topiques - Google Patents

Formulations topiques Download PDF

Info

Publication number
WO2011041609A3
WO2011041609A3 PCT/US2010/051001 US2010051001W WO2011041609A3 WO 2011041609 A3 WO2011041609 A3 WO 2011041609A3 US 2010051001 W US2010051001 W US 2010051001W WO 2011041609 A3 WO2011041609 A3 WO 2011041609A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
methods
topical formulations
provides
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/051001
Other languages
English (en)
Other versions
WO2011041609A2 (fr
Inventor
Servet Buyuktimkin
Nadir Buyuktimkin
Jagat Singh
John M. Newsam
Dominic King-Smith
Edward T. Kisak
Bradley S. Galer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvo Research Inc
Original Assignee
Nuvo Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvo Research Inc filed Critical Nuvo Research Inc
Priority to EP10762838A priority Critical patent/EP2482850A2/fr
Publication of WO2011041609A2 publication Critical patent/WO2011041609A2/fr
Publication of WO2011041609A3 publication Critical patent/WO2011041609A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques topiques, des méthodes de préparation, et des méthodes de traitement mettant en œuvre un inhibiteur sélectif de COX-2 utile pour le traitement de la douleur, en particulier la douleur associée à l'arthrose. Les compositions de l'invention offrent une bonne perméabilité et biodisponibilité sur le site cible. Dans certains modes de réalisation préférés, on décrit une composition comprenant étoricoxib, 2-amino-2-méthylpropanol (AMP), un épaississant cellulosique, et de l'urée.
PCT/US2010/051001 2009-09-30 2010-09-30 Formulations topiques Ceased WO2011041609A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10762838A EP2482850A2 (fr) 2009-09-30 2010-09-30 Formulations topiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24722209P 2009-09-30 2009-09-30
US61/247,222 2009-09-30

Publications (2)

Publication Number Publication Date
WO2011041609A2 WO2011041609A2 (fr) 2011-04-07
WO2011041609A3 true WO2011041609A3 (fr) 2011-05-26

Family

ID=43618884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/051001 Ceased WO2011041609A2 (fr) 2009-09-30 2010-09-30 Formulations topiques

Country Status (2)

Country Link
EP (1) EP2482850A2 (fr)
WO (1) WO2011041609A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2575813A1 (fr) * 2010-05-28 2013-04-10 Nuvo Research Inc. Formulation topique d'étoricoxib
TW201431572A (zh) 2012-12-21 2014-08-16 Teikoku Pharma Usa Inc 荷爾蒙及其它醫藥劑之經皮傳遞的組成物及方法
KR20170110083A (ko) 2014-12-23 2017-10-10 인털렉츄얼 프라퍼티 어쏘시에이츠, 엘엘씨 경피 투여를 위한 방법 및 제형
WO2019055880A2 (fr) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Méthode d'administration et de traitement

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096435A2 (fr) * 2001-05-31 2002-12-05 Pharmacia Corporation Composition d'inhibiteur selectif de cyclooxygenase-2, permeable a la peau
WO2004047816A1 (fr) * 2002-11-21 2004-06-10 Pharmacia Corporation Timbre transdermique inhibant de façon selective la cyclooxygenase-2
US20050096371A1 (en) * 2003-11-05 2005-05-05 Anandi Krishnan Topical pharmaceutical compositions
WO2008049020A2 (fr) * 2006-10-17 2008-04-24 Nuvo Research Gel de diclofénac

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096435A2 (fr) * 2001-05-31 2002-12-05 Pharmacia Corporation Composition d'inhibiteur selectif de cyclooxygenase-2, permeable a la peau
WO2004047816A1 (fr) * 2002-11-21 2004-06-10 Pharmacia Corporation Timbre transdermique inhibant de façon selective la cyclooxygenase-2
US20050096371A1 (en) * 2003-11-05 2005-05-05 Anandi Krishnan Topical pharmaceutical compositions
WO2008049020A2 (fr) * 2006-10-17 2008-04-24 Nuvo Research Gel de diclofénac

Also Published As

Publication number Publication date
EP2482850A2 (fr) 2012-08-08
WO2011041609A2 (fr) 2011-04-07

Similar Documents

Publication Publication Date Title
WO2008132229A3 (fr) Solutions et compositions hautement concentrées en insuline
IL196280A0 (en) Use of ampk-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them
WO2008049020A3 (fr) Gel de diclofénac
MX277822B (es) Derivados de urea de tropano, su preparacion y su aplicacion terapeutica.
IL194865A0 (en) Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
EP2431366A4 (fr) Nouveau composé conjugué de chlore e6-acide folique, procédé de préparation de ce composé et composition pharmaceutique contenant ledit composé pour le traitement du cancer
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
IL224288A (en) Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use
WO2012046030A3 (fr) Inhibiteurs de phosphodiestérase
WO2010048358A3 (fr) Inhibiteurs à base d'éthoxyphénylméthyle de sglt2
IL223463A (en) Urea History, Pharmaceutical Preparations Containing and Uses
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2011113060A3 (fr) Composés antiviraux et procédés d'utilisation de ceux-ci
WO2010021607A3 (fr) Préparation pharmaceutique
WO2011060195A3 (fr) Formulation eutectique topique
IL209593A (en) Diamino-Pyridine, Pyrimidine and Pyridazine Derivatives, Pharmaceutical Preparations Containing Them and Uses as Modulators of Histamine H4 Receptor
IL195813A0 (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
EP2190445A4 (fr) Pousses de grenade, préparations issues de celles-ci et compositions les comprenant
WO2011103018A8 (fr) Dérivés d'imidazole fusionnés et substitués, compositions pharmaceutiques et procédés d'utilisation associés
BRPI0907228A2 (pt) Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos
BRPI0720323A2 (pt) composto, método de tratamento, composição farmacêutica e uso do composto
WO2010025370A3 (fr) Préparation de ranolazine
WO2011041609A3 (fr) Formulations topiques
WO2012019428A8 (fr) Dérivés de benzohydrol, procédé de préparation et utilisation pharmaceutique de ceux-ci
WO2011107866A3 (fr) Dérivés silyliques de polysaccharides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10762838

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010762838

Country of ref document: EP